𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer

✍ Scribed by Edward S. Kim; Ann M. Mauer; William N. William Jr; Hai T. Tran; Diane Liu; Jack J. Lee; Paul Windt; Waun K. Hong; Everett E. Vokes; Roy S. Herbst

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
316 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I-II study of docetaxel-ifosfami
A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer
✍ Christos Kosmas; Nicolas B. Tsavaris; Thomas Makatsoris; Adimchi Onyenadum; Mari 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB

## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≤2, n

A Phase II trial of gemcitabine and doce
A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma
✍ Irina E. Popa; Kathleen Stewart; Frederick P. Smith; Naiyer A. Rizvi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

## Abstract ## BACKGROUND The goals of the current study were to determine the safety and efficacy of a nonplatinum‐containing doublet, gemcitabine and docetaxel, in the treatment of patients with chemotherapy‐naive nonsmall cell lung carcinoma (NSCLC). ## METHODS Thirty‐two patients with advanc

Phase I trial of docetaxel and vinorelbi
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma
✍ Vincent A. Miller; Kenneth K. Ng; Lee M. Krug; Wendy Perez; Barbara Pizzo; Rober 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## Background: With preclinical evidence of synergy, this dose-finding trial examining the combination of docetaxel and vinorelbine given with prophylactic filgrastim for the treatment of patients with nonsmall cell lung carcinoma was undertaken. ## Methods: Twenty-seven patients with advanced no

A phase II study of weekly docetaxel plu
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma
✍ Ji-Youn Han; Dae Ho Lee; Hae Young Kim; Eun Kyung Hong; Sung Min Yoon; Jong Ho C 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract ## BACKGROUND Docetaxel is an active agent in advanced nonsmall‐cell lung carcinoma (NSCLC) and demonstrates preclinical and clinical synergism with capecitabine. We conducted the current Phase II study to evaluate the efficacy and safety of the docetaxel/capecitabine combination in ch